As demand for GLP-1 medications continues to rise, employers are facing increasing pressure to balance employee access with benefit cost management. The Alight GLP-1 Health Reimbursement Account (HRA) offers a flexible solution that enables your organization to reimburse employees for GLP-1 medications while maintaining control over eligibility, funding levels and overall cost exposure.
Join this webinar to learn how the Alight GLP-1 HRA helps you provide access to FDA-approved medications such as Wegovy® and Zepbound®, as well as compounded alternatives, through a simple direct-to-consumer experience. Employees can purchase medications directly through the platform or receive reimbursement for purchases made at local pharmacies.
Discover how Alight brings together HRA administration, digital engagement, reporting and ecosystem integrations into a seamless solution designed to support both employee wellbeing and your organizational objectives.
What you'll learn
- How the Alight GLP-1 HRA enables employers to offer GLP-1 medication support while retaining budget control
- Flexible reimbursement options for FDA-approved and compounded GLP-1 medications
- Strategies for managing eligibility, funding and utilization
- How employees access medications through direct purchase or pharmacy reimbursement
- The value of integrated administration, reporting and digital engagement capabilities
- How you can enhance benefit offerings while addressing rising demand for weight management solutions
